Published in J Virol on April 01, 1993
Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol (1995) 1.35
Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Res (1993) 1.14
Ribozyme-mediated RNA degradation in nuclei suspension. Nucleic Acids Res (1995) 0.86
Ribozyme mediated degradation of beta-amyloid peptide precursor mRNA in COS-7 cells. Nucleic Acids Res (1994) 0.78
Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (1988) 8.74
A small catalytic oligoribonucleotide. Nature (1987) 8.73
Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell (1987) 8.19
Autolytic processing of dimeric plant virus satellite RNA. Science (1986) 6.14
Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 4.49
Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry (1990) 3.64
Self-cleaving transcripts of satellite DNA from the newt. Cell (1987) 3.37
The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. Virology (1989) 3.29
Virus-lymphocyte interactions. IV. Molecular characterization of LCMV Armstrong (CTL+) small genomic segment and that of its variant, Clone 13 (CTL-). Virology (1988) 3.22
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol (1992) 2.85
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
The primary structure of the lymphocytic choriomeningitis virus L gene encodes a putative RNA polymerase. Virology (1989) 2.25
Characterization of messenger ribonucleoprotein and messenger RNA from KB cells. Proc Natl Acad Sci U S A (1972) 2.20
Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci U S A (1989) 2.14
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc Natl Acad Sci U S A (1991) 2.09
Protein structure of lymphocytic choriomeningitis virus: evidence for a cell-associated precursor of the virion glycopeptides. Virology (1979) 2.00
A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol (1993) 1.86
Gene therapy for cancer. Lancet (1992) 1.81
Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol (1992) 1.68
Stereochemistry of RNA cleavage by the Tetrahymena ribozyme and evidence that the chemical step is not rate-limiting. Science (1989) 1.68
Arenavirus gene structure and organization. Curr Top Microbiol Immunol (1987) 1.50
Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res (1989) 1.46
Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol (1990) 1.34
Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. EMBO J (1992) 1.31
Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J Mol Biol (1992) 1.20
Mutations in a nonconserved sequence of the Tetrahymena ribozyme increase activity and specificity. Cell (1991) 1.20
A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination. Proc Natl Acad Sci U S A (1992) 1.12
Inhibition of human immunodeficiency virus type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligodeoxyribonucleotides. J Gen Virol (1989) 1.09
RNA enzymes (ribozymes) as antiviral therapeutic agents. Trends Biotechnol (1990) 1.08
Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J Biol Chem (1990) 1.03
Ribozymes which cleave arenavirus RNAs: identification of susceptible target sites and inhibition by target site secondary structure. J Virol (1992) 1.03
Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis (1990) 1.02
A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells. FEBS Lett (1990) 0.98
Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A (1990) 0.97
In vivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy. AIDS Res Hum Retroviruses (1991) 0.95
Treatment of AIDS with combinations of antiretroviral agents. Am J Med (1991) 0.93
Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J Gen Virol (1990) 0.91
Antisense oligonucleotide inhibition of encephalomyocarditis virus RNA translation. Eur J Biochem (1989) 0.89
Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene (1992) 0.89
The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul (1992) 0.89
Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Transplant Proc (1991) 0.87
AZT resistance in isolates of HIV. Immunodefic Rev (1991) 0.85
Herpes simplex virus in immunocompromised patients: growing evidence of drug resistance. Oral Surg Oral Med Oral Pathol (1991) 0.82
Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. Lancet (1991) 0.81
Selective cleavage of closely-related mRNAs by synthetic ribozymes. Nucleic Acids Res (1992) 0.80
The consensus sequence YGTGTTYY located downstream from the AATAAA signal is required for efficient formation of mRNA 3' termini. Nucleic Acids Res (1985) 7.18
Fine dissection of a nine amino acid glycoprotein epitope, a major determinant recognized by lymphocytic choriomeningitis virus-specific class I-restricted H-2Db cytotoxic T lymphocytes. J Exp Med (1988) 4.75
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol (2001) 3.08
LCMV-specific, class II-restricted cytotoxic T cells in beta 2-microglobulin-deficient mice. Science (1992) 2.98
Replication origins and a sequence involved in coordinate induction of the immediate-early gene family are conserved in an intergenic region of herpes simplex virus. Nucleic Acids Res (1984) 2.35
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J Immunol (2000) 2.15
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol (1989) 2.05
Immediate-early mRNA-2 of herpes simplex viruses types 1 and 2 is unspliced: conserved sequences around the 5' and 3' termini correspond to transcription regulatory signals. Nucleic Acids Res (1983) 2.01
Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. Nature (1999) 1.99
Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers. J Immunol (2000) 1.97
Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 1.87
The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol (1995) 1.83
DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol (1995) 1.83
A modular system for the assay of transcription regulatory signals: the sequence TAATGARAT is required for herpes simplex virus immediate early gene activation. Nucleic Acids Res (1985) 1.75
DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol (1997) 1.69
A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc Natl Acad Sci U S A (1999) 1.49
Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol (1998) 1.46
Vaccination to prevent persistent viral infection. J Virol (1993) 1.39
DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol (1998) 1.34
Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology. Virology (2000) 1.32
DNA immunization. Trends Microbiol (1996) 1.26
The junctions between the repetitive and the short unique sequences of the herpes simplex virus genome are determined by the polypeptide-coding regions of two spliced immediate-early mRNAs. J Gen Virol (1984) 1.24
Antigen-specific regulation of T cell-mediated cytokine production. Immunity (2000) 1.24
Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol (2001) 1.20
DNA immunization to prevent autoimmune diabetes. J Clin Invest (1999) 1.20
An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A (2000) 1.17
CTL escape viral variants. II. Biologic activity in vivo. Virology (1995) 1.15
A brief instrument for longitudinal monitoring of mood states. Psychiatry Res (1984) 1.13
Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization. J Virol (2000) 1.13
A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination. Proc Natl Acad Sci U S A (1992) 1.12
Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J Neuropathol Exp Neurol (1998) 1.11
Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization. J Virol (2000) 1.10
Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities. J Virol (2001) 1.06
Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol (1999) 1.04
Virus-induced diabetes in a transgenic model: role of cross-reacting viruses and quantitation of effector T cells needed to cause disease. J Virol (2000) 1.04
Clinical implications of dysregulated cytokine production. J Mol Med (Berl) (2000) 1.04
DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site. Vaccine (1997) 1.03
Viruses can silently prime for and trigger central nervous system autoimmune disease. J Neurovirol (2001) 1.03
Ribozymes which cleave arenavirus RNAs: identification of susceptible target sites and inhibition by target site secondary structure. J Virol (1992) 1.03
Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge. J Virol (1997) 1.03
The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol (1999) 1.02
Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther (2002) 1.01
Biometeorology. Can Med Assoc J (1985) 0.99
Polymorphism of cytotoxic T-lymphocyte clones that recognize a defined nine-amino-acid immunodominant domain of lymphocytic choriomeningitis virus glycoprotein. J Virol (1989) 0.98
CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol (2001) 0.95
Infradian rhythms. A comparison of affective disorders and normal persons. Arch Gen Psychiatry (1985) 0.95
Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol (1993) 0.94
Quantitative and qualitative analyses of the immune responses induced by a multivalent minigene DNA vaccine. Vaccine (2000) 0.94
Altered tissue distribution of viral replication and T cell spreading is pivotal in the protection against fatal lymphocytic choriomeningitis in mice after neutralization of IFN-alpha/beta. J Immunol (1994) 0.92
Preferential coxsackievirus replication in proliferating/activated cells: implications for virus tropism, persistence, and pathogenesis. Curr Top Microbiol Immunol (2008) 0.92
DNA immunization: effects of vehicle and route of administration on the induction of protective antiviral immunity. FEMS Immunol Med Microbiol (1996) 0.92
A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listeria monocytogenes infection. Infect Immun (1996) 0.91
Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J Virol (1998) 0.91
Enhancing DNA immunization. Virology (2000) 0.90
Weather and infradian rhythms in self-reports of health, sleep and mood measures. J Psychosom Res (1982) 0.90
Periodicities in self-reports of health, sleep and mood variables. J Psychosom Res (1978) 0.89
Vaccination protects beta 2 microglobulin deficient mice from immune mediated mortality but not from persisting viral infection. Vaccine (1996) 0.87
Animal models using lymphocytic choriomeningitis virus. Curr Protoc Immunol (2001) 0.87
Plasmid DNA vaccines are effective in the absence of IFNgamma. Virology (1999) 0.87
Limiting the available T cell receptor repertoire modifies acute lymphocytic choriomeningitis virus-induced immunopathology. J Neuroimmunol (1994) 0.87
Novel LCMV-specific H-2k restricted CTL clones recognize internal viral gene products and cause CNS disease. J Neuroimmunol (1992) 0.87
Effect of immune priming on Borna disease. J Virol (1999) 0.86
A rapid, inexpensive method for eluting DNA from agarose or acrylamide gel slices without using toxic or chaotropic materials. Biotechniques (1992) 0.84
Antisense-mediated resistance to measles virus infection in HeLa cells. J Infect Dis (1997) 0.82
Intravenous administration of human embryonic stem cell-derived neural precursor cells attenuates cuprizone-induced central nervous system (CNS) demyelination. Neuropathol Appl Neurobiol (2011) 0.82
Use of a high-affinity peptide that aborts MHC-restricted cytotoxic T lymphocyte activity against multiple viruses in vitro and virus-induced immunopathologic disease in vivo. Virology (1999) 0.82
Virus encoding an encephalitogenic peptide protects mice from experimental allergic encephalomyelitis. J Neuroimmunol (1996) 0.82
Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing-remitting experimental allergic encephalomyelitis. J Neuroimmunol (1999) 0.81
Genetic dependence of the electroencephalogram bispectrum. Electroencephalogr Clin Neurophysiol (1985) 0.78
A rapid and simple method for determining the DNA sequences of fragments inserted into vaccinia virus. Biotechniques (1993) 0.78
Rapid accumulation of measles virus leader RNA in the nucleus of infected HeLa cells and human lymphoid cells. J Virol (1991) 0.78
The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes. Gene Ther (2003) 0.78
A spectral method for removing eye movement artifacts from the EEG. Electroencephalogr Clin Neurophysiol (1978) 0.78
DNA vaccination to treat autoimmune diabetes. Ann Med (2000) 0.77
EEG frequency patterns associated with hallucinations in schizophrenia and "creativity" in normals. Biol Psychiatry (1978) 0.77
Silver staining of nucleic acids. Applications in virus research and in diagnostic virology. J Virol Methods (1983) 0.77
Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine. Hum Gene Ther (2001) 0.77
Induction of antiviral antibodies by DNA immunization requires neither perforin-mediated nor CD8(+)-T-cell-mediated lysis of antigen-expressing cells. J Virol (1999) 0.76
Use of a nonviral vector to express a chimeric tRNA-ribozyme against lymphocytic choriomeningitis virus: cytoplasmic accumulation of a catalytically competent transcript but minimal antiviral effect. Antisense Nucleic Acid Drug Dev (1997) 0.76
Multivalent minigene vaccines against infectious disease. Curr Opin Mol Ther (1999) 0.75
Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus. Antisense Res Dev (1995) 0.75
Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol (1993) 0.75
Evoked potential maps in learning disabled children. Electroencephalogr Clin Neurophysiol (1986) 0.75